Who
Rick E. Winningham
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Theravance Biopharma; Director, Jazz Pharmaceuticals; Director, OncoMed Pharmaceuticals; Chief Executive Officer, Innoviva.
In numbers
- Trades disclosed
- 252
- Buys
- 4
- Sells
- 28
- Bought
- $1.4M
- Sold
- $39.4M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 8 Feb 2006
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —1,382,272 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —151,875 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —76,875 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —515,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —23,400 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —92,567 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —515,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —1,382,272 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —151,875 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —76,875 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —23,400 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —92,567 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,42514 at $244.64 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $408K1,692 at $241.39 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $3,42514 at $244.64 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $340K20,034 at $16.95 | filing |
| 20 Aug 2026filed 24 Aug 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code F | $340K20,034 at $16.95 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
News
Jazz Pharmaceuticals gets Cramer's vote of confidenceJAZZ · aol.com · 14 Oct 2026Critical Analysis: vTv Therapeutics (NASDAQ:VTVT) and Jazz Pharmaceuticals (NASDAQ:JAZZ)JAZZ · tickerreport.com · 12 Oct 2026Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'JAZZ · cnbc.com · 10 Oct 2026
0 headlines in the last 90 days name Rick E. Winningham; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.